Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Weekly News Recap #Phispers
1. (r)-2-(7-((4-cyclo-pentyl-3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydro-cyclopenta(b)indol-3-yl)acetic Acid)
1. 1206123-37-6
2. Apd334
3. Apd-334
4. Etrasimod [usan]
5. 6wh8495mmh
6. Apd-334(free Acid)
7. Chembl3358920
8. Etrasimod (usan)
9. 1206123-37-6 (free Base)
10. (r)-2-(7-((4-cyclopentyl-3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid
11. (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl) Acetic Acid
12. 2-[(3r)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic Acid
13. Etrasimod(apd334)
14. Etrasimod [inn]
15. Etrasimod [who-dd]
16. Unii-6wh8495mmh
17. Apd334apd334
18. Gtpl9331
19. Schembl1919311
20. Bcp19558
21. Ex-a1633
22. Bdbm50041691
23. Akos032944972
24. Zinc117522788
25. Apd334-003
26. Compound 4 [pmid: 25516790]
27. Cs-6181
28. Db14766
29. Ac-35444
30. Hy-12789
31. D10930
32. F10118
33. Q27265630
34. ((3r)-7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid
35. (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid
36. Cyclopent(b)indole-3-acetic Acid, 7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydro-, (3r)-
Molecular Weight | 457.5 g/mol |
---|---|
Molecular Formula | C26H26F3NO3 |
XLogP3 | 6.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 457.18647818 g/mol |
Monoisotopic Mass | 457.18647818 g/mol |
Topological Polar Surface Area | 62.3 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 695 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Lead Product(s): Obefazimod,Etrasimod
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2024
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Abivax Presents Preclinical Data for UC Therapy with Obefazimod and Etrasimod
Details : Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2024
Details:
Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dysentery.
Lead Product(s): Etrasimod,Corticosteroid
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2024
Lead Product(s) : Etrasimod,Corticosteroid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
Details : Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dysentery.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2024
Details:
Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Etrasimod,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2023
Lead Product(s) : Etrasimod,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2023
Details:
Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Colitis, Ulcerative.
Lead Product(s): Etrasimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 06, 2023
Lead Product(s) : Etrasimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.
Details : Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 06, 2023
Details:
Estraimod is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Estraimod,Etrasimod
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 21, 2023
Lead Product(s) : Estraimod,Etrasimod
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants
Details : Estraimod is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 21, 2023
Details:
Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Etrasimod,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 17, 2023
Lead Product(s) : Etrasimod,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 17, 2023
Details:
Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.
Lead Product(s): Etrasimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2022
Lead Product(s) : Etrasimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Details : Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2022
Details:
Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator.
Lead Product(s): Etrasimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: $6,700.0 million Upfront Cash: $6,700.0 million
Deal Type: Acquisition March 11, 2022
Lead Product(s) : Etrasimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $6,700.0 million
Deal Type : Acquisition
Pfizer Completes Acquisition of Arena Pharmaceuticals
Details : Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulato...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $6,700.0 million
March 11, 2022
Details:
Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena and it's pipeline including lead product etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator currently in development for a range of immuno-inflammatory diseases.
Lead Product(s): Etrasimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: $6,700.0 million Upfront Cash: $6,700.0 million
Deal Type: Acquisition December 13, 2021
Lead Product(s) : Etrasimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $6,700.0 million
Deal Type : Acquisition
Pfizer to Acquire Arena Pharmaceuticals
Details : Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena and it's pipeline including lead product etrasimod, an oral, selective sphingosine 1-phosphate receptor modulator currently in development for a range of immuno-inf...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $6,700.0 million
December 13, 2021
Details:
Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.
Lead Product(s): Etrasimod,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 29, 2021
Lead Product(s) : Etrasimod,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Etrasimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2021
Regulatory Info :
Registration Country : Australia
Brand Name : Velsipity
Dosage Form :
Dosage Strength :
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Velsipity
Dosage Form :
Dosage Strength :
Packaging : 28
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Norway
Brand Name : Wellsipity
Dosage Form : Tablet, film-coated
Dosage Strength : 2 mg
Packaging : Blisterpakning 28item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Velsipity
Dosage Form : Film Coated Tablet
Dosage Strength : 2mg
Packaging :
Approval Date : 10/09/2024
Application Number : 69377
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Brand Name : Wellsipity
Dosage Form : Tablet, film-coated
Dosage Strength : 2 mg
Packaging : Blisterpakning 28item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Velsipity
Dosage Form : Film Coated Tablet
Dosage Strength : 2mg
Packaging :
Approval Date : 10/09/2024
Application Number : 69377
Regulatory Info : Allowed
Registration Country : Switzerland
Global Sales Information
Market Place
Reply
31 Jul 2024
Reply
21 Dec 2023
ABOUT THIS PAGE
31
PharmaCompass offers a list of Etrasimod API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Etrasimod manufacturer or Etrasimod supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Etrasimod manufacturer or Etrasimod supplier.
PharmaCompass also assists you with knowing the Etrasimod API Price utilized in the formulation of products. Etrasimod API Price is not always fixed or binding as the Etrasimod Price is obtained through a variety of data sources. The Etrasimod Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Etrasimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Etrasimod, including repackagers and relabelers. The FDA regulates Etrasimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Etrasimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Etrasimod manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Etrasimod supplier is an individual or a company that provides Etrasimod active pharmaceutical ingredient (API) or Etrasimod finished formulations upon request. The Etrasimod suppliers may include Etrasimod API manufacturers, exporters, distributors and traders.
click here to find a list of Etrasimod suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Etrasimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Etrasimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Etrasimod GMP manufacturer or Etrasimod GMP API supplier for your needs.
A Etrasimod CoA (Certificate of Analysis) is a formal document that attests to Etrasimod's compliance with Etrasimod specifications and serves as a tool for batch-level quality control.
Etrasimod CoA mostly includes findings from lab analyses of a specific batch. For each Etrasimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Etrasimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Etrasimod EP), Etrasimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Etrasimod USP).